Initial Implications from the Pricing of Humira Biosimilars
The world’s highest-selling drug, Humira, is facing its first competition from a copycat biosimilar. The entry of its first “generic” competitor represents a widely-anticipated test of biosimilars’ ability to increase price competition, savings, and patient access. In this piece, we briefly summarize how the new product is likely to affect markets. Unlike most drugs, the […]